Merus Announces IND Clearance for MCLA-145
MCLA-145 is a full-length human bispecific antibody binding to PD-L1 and CD137
UTRECHT, The Netherlands, Jan. 07, 2019 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage immuno-oncology company developing Biclonics®, innovative full-length human bispecific antibody therapeutics, today announced the U.S. Food and Drug Administration (FDA) has accepted the Investigational New Drug (IND) application for MCLA-145, a first-in-class PD-L1 x CD137 Biclonics® being developed in collaboration with Incyte (Nasdaq: INCY), for the treatment of solid tumors.
“We are pleased to announce the IND authorization to proceed from the FDA and to disclose more details around our latest Biclonics® program today,” said Andres Sirulnik, M.D., Ph. D., Executive Vice President and Chief Medical Officer of Merus. “Our preclinical work has demonstrated that MCLA-145 has the potential to overcome the known side effects of CD137 agonists currently in development and to address a significant unmet need in patient populations not benefitting from current immunotherapeutic agents. We expect to initiate the clinical trial program for MCLA-145 during the second quarter of 2019 and we look forward to continuing our collaboration with Incyte on MCLA-145’s global development.”
Discovered through an unbiased functional screening of multiple immunomodulatory target combinations, MCLA-145 is a Biclonics® T-cell agonist that binds with high affinity and specificity to human PD-L1 and CD137 in preclinical models. The unique immunostimulatory profile of MCLA-145 derives from the ability to potently activate immune effector cells in the context of the tumor microenvironment while simultaneously blocking inhibitory signals in the same immune cell population.
Merus is developing MCLA-145 as part of a collaboration entered into with Incyte in December 2016 to potentially develop and commercialize up to 11 bispecific and monospecific antibodies from the Merus Biclonics® platform. Under the terms of the collaboration, Merus will retain all rights to develop and commercialize MCLA-145, if approved, in the United States, while Incyte has rights to develop and commercialize MCLA-145, if approved, outside the United States.
About Merus N.V.
Merus is a clinical-stage immuno-oncology company developing innovative full-length human bispecific antibody therapeutics, referred to as Biclonics®. Biclonics, which are based on the full-length IgG format, are manufactured using industry standard processes and have been observed in preclinical and clinical studies to have several of the same features of conventional human monoclonal antibodies, such as long half-life and low immunogenicity. For additional information, please visit Merus’ website, www.merus.nl.
Forward Looking Statement
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation statements regarding the characteristics and immunostimulatory profile of MCLA-145; the potential for MCLA-145 to overcome known side effects of CD137 agonists currently in development and to address a significant unmet need in patient populations not benefitting from current immunotherapeutic agents; the commencement and timing of the clinical trial program for MCLA-145; the continuing collaboration with Incyte on MCLA-145’s global development, and potential to develop and commercialize up to 11 bispecifc and monospecific antibodies from the Merus Biclonics® platform; and whether any of the programs under the collaboration will be successful, including for MCLA-145. .
These forward-looking statements are based on management’s current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the following: our need for additional funding, which may not be available and which may require us to restrict our operations or require us to relinquish rights to our technologies or Biclonics® and bispecific antibody candidates; potential delays in regulatory approval, which would impact our ability to commercialize our product candidates and affect our ability to generate revenue; the lengthy and expensive process of clinical drug development, which has an uncertain outcome; the unpredictable nature of our early stage development efforts for marketable drugs; potential delays in enrollment of patients, which could affect the receipt of necessary regulatory approvals; our reliance on third parties to conduct our clinical trials and the potential for those third parties to not perform satisfactorily; we may not identify suitable Biclonics® or bispecific antibody candidates under our collaboration with Incyte or Incyte may fail to perform adequately under our collaboration; our reliance on third parties to manufacture our product candidates, which may delay, prevent or impair our development and commercialization efforts; protection of our proprietary technology; our patents may be found invalid, unenforceable, circumvented by competitors and our patent applications may be found not to comply with the rules and regulations of patentability; we may fail to prevail in potential lawsuits for infringement of third-party intellectual property; and our registered or unregistered trademarks or trade names may be challenged, infringed, circumvented or declared generic or determined to be infringing on other marks.
These and other important factors discussed under the caption “Risk Factors” in our Annual Report on Form 20-F filed with the Securities and Exchange Commission, or SEC, on April 28, 2017, and our other reports filed with the SEC, could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management’s estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change, except as required under applicable law. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release.
Investor and Media Inquiries:
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire
Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire
Kommuniké från Stockwiks extra bolagsstämma den 3 juni 20203.6.2020 11:00:00 CEST | Pressemelding
Extra bolagsstämma i Stockwik Förvaltning AB (publ) avhölls den 3 juni 2020, varvid följande beslut fattades. Stämman godkände förvärvet av Admit Ekonomi AB (”Admit”) så som närståendetransaktion enligt kap. 16 a aktiebolagslagen. Som tidigare offentliggjorts träffade Stockwik den 11 maj 2020 avtal om förvärv av samtliga aktier i Admit som ägs via bolag av styrelseledamoten Olof Nordberg (”Säljaren”). Köpeskillingen om 30 MSEK på skuldfri basis består av en kontantbetalning, en revers och en riktad nyemission av aktier i Stockwik. Enligt aktieöverlåtelseavtalet uppgår kontantbetalningen till 10 MSEK (före eventuell justering med ett belopp motsvarande Admits nettokassa/-skuld vid tillträdesdagen), reversen till 15 MSEK och de nyemitterade aktiernas teckningslikvid till 5 MSEK Stämman beslutade om riktad nyemission av aktier att utges som en del av köpeskillingen i förvärvet av Admit (”Vederlagsaktierna”). Genom nyemissionen kommer aktiekapitalet att ökas med högst 67.567,51 kronor geno
Cargotec’s Kalmar and MacGregor to help drive development of connected automated waterborne transport through participation in AEGIS project3.6.2020 11:00:00 CEST | Press release
CARGOTEC CORPORATION, PRESS RELEASE, 3 JUNE 2020 AT NOON (EEST) Cargotec’s Kalmar and MacGregor to help drive development of connected automated waterborne transport through participation in AEGIS project Cargotec’s Kalmar and MacGregor have announced their joint participation in AEGIS (Advanced, Efficient and Green Intermodal Systems), a three-year project funded by the EU’s Horizon 2020 Research and Innovation programme. The focus of the AEGIS project is on integrating smaller ships, inland transport and short-sea shipping with larger terminals to create a completely new European transport system. The goal is to develop more flexible and user-centric transport, improve services to rural and urban areas, and revitalise regional ports and city terminals. Kalmar and MacGregor will be the technology providers for the project. The project has been selected by the EU Commission to show that autonomous ships and port automation technologies can make waterborne transport much more flexible a
Result of Riksbank´s purchases of Commercial Paper3.6.2020 10:00:00 CEST | Press release
Auction date200603Requested volume, SEK mln4,000 Credit rating class1Term3MRequested volume, SEK mln1,000 +/-Fixed purchase rate0.55 %Total bid amount, SEK mln0,000Prel. accepted volume, SEK mln0,000Percentage allotedn/aNumber of bids0 Credit rating class1Term6MRequested volume, SEK mln1,000 +/-Fixed purchase rate0.65 %Total bid amount, SEK mln115Prel. accepted volume, SEK mln115Percentage alloted100.00 %Number of bids1 Credit rating class2Term3MRequested volume, SEK mln1,000 +/-Fixed purchase rate0.85 %Total bid amount, SEK mln0,000Prel. accepted volume, SEK mln0,000Percentage allotedn/aNumber of bids0 Credit rating class2Term6MRequested volume, SEK mln1,000 +/-Fixed purchase rate0.95 %Total bid amount, SEK mln0,000Prel. accepted volume, SEK mln0,000Percentage allotedn/aNumber of bids0
Sweden’s Första AP-fonden (AP1) Selects eVestment for Asset Manager Monitoring3.6.2020 09:00:10 CEST | Press release
STOCKHOLM, Sweden and LONDON, June 03, 2020 (GLOBE NEWSWIRE) -- Swedish public pension fund Första AP-fonden (AP1) will add to its asset manager selection capabilities by adopting asset manager monitoring capabilities from eVestment, a global leader in institutional investment data and analytics. As pensions around the world search for investment returns at acceptable levels of risk, data providers like eVestment have an important role in collecting and organizing data used in the manager assessment and monitoring processes. With 4000+ asset managers from around the world reporting data to eVestment on more than 25,000 institutional strategies, eVestment offers the most comprehensive look at trends across the institutional landscape, at the universe, firm and product levels. “As a leading source of institutional manager data, both in local markets and globally, eVestment provides a holistic view of the managers and strategies available,” said eVestment Managing Director for EMEA J.P. Q
AP1 väljer eVestment som analysverktyg för externa kapitalförvaltare3.6.2020 09:00:10 CEST | Pressemelding
STOCKHOLM och LONDON, June 03, 2020 (GLOBE NEWSWIRE) -- Den statliga svenska pensionsfonden Första AP-fonden (AP1) inleder ett samarbete med eVestment som leverantör av data för analys av externa kapitalförvaltare. eVestment är en global ledare inom investeringsdata och investeringsanalys för institutionella investerare. När pensionsfonder över hela världen söker efter investeringsstrategier som ger avkastning till en given risknivå, är eVestment en viktig samarbetspartner för att samla in data för analys och för att organisera densamma. Över 4 000 kapitalförvaltare från hela världen levererar data till eVestment där mer än 25 000 institutionella strategier ingår. eVestment levererar en heltäckande översikt såväl på en övergripande nivå som på en företags- och produktnivå. – Som en av de ledande leverantörerna av data om institutionella förvaltare, hjälper eVestment till att ge en helhetsbild av tillgängliga förvaltare och strategier, både lokalt och globalt. Kontinuerlig uppföljning ä
Rovio Entertainment has acquired Darkfire Games - Copenhagen based mobile games studio3.6.2020 08:30:00 CEST | Press release
Rovio Entertainment Corporation Press Release Rovio Entertainment has acquired Darkfire Games - Copenhagen based mobile games studio June 3, 2020 - Espoo - Rovio Entertainment Corp. has acquired a free-to-play (F2P) mobile games studio Darkfire Games (formerly Wargaming Denmark), focused on Role Playing Games (RPG). Rovio acquired all of the outstanding shares of Darkfire Games for an undisclosed sum on June 3, 2020, and the wholly-owned Rovio subsidiary will become Rovio Copenhagen. Rovio Copenhagen will continue to operate as an independent studio focusing on mobile RPGs. At present, the studio comprises 20 gaming industry veterans with vast expertise in making RPGs. As part of the acquisition, Rovio takes on the studio’s currently soft-launched mobile RPG, Darkfire Heroes. The game’s development will continue in Copenhagen, with Rovio providing synergies and support for the studio in central functions and areas such as user acquisition, technology, analytics and live operations. “We